S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:ALGS

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

$0.98
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.92
$1.00
50-Day Range
$0.64
$1.13
52-Week Range
$0.54
$1.38
Volume
312,472 shs
Average Volume
504,012 shs
Market Capitalization
$74.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aligos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.96mentions of Aligos Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.24 out of 5 stars

Medical Sector

441st out of 939 stocks

Biological Products, Except Diagnostic Industry

70th out of 158 stocks

ALGS stock logo

About Aligos Therapeutics Stock (NASDAQ:ALGS)

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ALGS Stock Price History

ALGS Stock News Headlines

Aligos Therapeutics Inc (ALGS)
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Recap: Aligos Therapeutics Q4 Earnings
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Tracking Baker Brothers Portfolio - Q4 2023 Update
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics Inc Ordinary Shares
See More Headlines
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALGS
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-87,680,000.00
Net Margins
-607.03%
Pretax Margin
-559.49%

Debt

Sales & Book Value

Annual Sales
$15.53 million
Book Value
$1.23 per share

Miscellaneous

Free Float
63,184,000
Market Cap
$74.16 million
Optionable
Optionable
Beta
2.34
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Lawrence M. Blatt MBA (Age 62)
    Ph.D., CEO, President & Chairman of the Board
    Comp: $832.73k
  • Dr. Julian A. Symons DPHIL (Age 62)
    Executive VP & Chief Scientific Officer
    Comp: $618.66k
  • Ms. Lesley Ann Calhoun CPA (Age 58)
    Executive VP & CFO
  • Kristina Engeseth
    VP and Head of People & Culture
  • Dr. Matthew W. McClure M.D. (Age 52)
    Executive VP & Chief Medical Officer
  • Dr. Sushmita M. Chanda DABT (Age 57)
    Ph.D., Executive Vice President of Translational Safety Sciences
  • Dr. David B. Smith Ph.D.
    Executive VP & Head of Chemical Operations
  • Dr. Tse-I Lin Ph.D.
    VP of Early Compound Development & Belgian Site Head

ALGS Stock Analysis - Frequently Asked Questions

How have ALGS shares performed in 2024?

Aligos Therapeutics' stock was trading at $0.6640 on January 1st, 2024. Since then, ALGS stock has increased by 47.6% and is now trading at $0.98.
View the best growth stocks for 2024 here
.

When is Aligos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALGS earnings forecast
.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.03. The firm earned $1.54 million during the quarter. Aligos Therapeutics had a negative trailing twelve-month return on equity of 116.41% and a negative net margin of 607.03%.

When did Aligos Therapeutics IPO?

Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

Who are Aligos Therapeutics' major shareholders?

Aligos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.12%), Altitude Crest Partners Inc. (3.80%), Hhlr Advisors LTD. (2.54%), Opaleye Management Inc. (1.73%), Newtyn Management LLC (1.67%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALGS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners